Home
Mesoblast

Mesoblast Market Share Analysis for November 2025

Mesoblast Limited is an Australian regenerative medicine company. It seeks to provide treatments for inflammatory ailments, cardiovascular disease, and back pain. The company is led by Silviu Itescu, who founded the company in 2004.

Health > Biotechnology and Pharmaceuticals

Domainmesoblast.com

Year Founded2004

Employees51 - 200

Annual Revenue$5M - $10M

Mesoblast

Mesoblast (including company regionals)

mesoblast.com

See more website traffic and engagement information

Mesoblast Revenue up to November 2025 is 5M - 10M

revenue generated by Mesoblast top domains

Mesoblast top domains revenue over 3 years

Revenue for Mesoblast top domains

mesoblast.com5M - 10M

See more with Sales Intelligence

Total visits to Mesoblast's top domains

Understand Mesoblast market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

mesoblast.com10.2K

See more with Sales Intelligence

Avg. visit duration in Mesoblast's top domains

Analyze Mesoblast engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

mesoblast.com00:00:40

See more with Sales Intelligence

Avg. pageviews on Mesoblast's top domains

See how Mesoblast keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

mesoblast.com2.04

See more with Sales Intelligence

Mesoblast top competitors by domain

Top similar sites in November 2025, ranked by their affinity

osiris.comCompany NameOsiris Therapeutics, Inc.Employees201 - 500HQUnited States, Maryland, ColumbiaAnnual revenue$100M - $200MTotal visits--Health > Biotechnology and Pharmaceuticals

Top technologies used by Mesoblast

These are the website technologies, by industry, used by Mesoblast top domains

Content Management System (3)

WordPress

Conversion & Analytics (2)

Google Analytics

Mobile (2)

Meta Viewport

Social (2)

Twitter

More Technologies

5

See all

News & Signals from Mesoblast

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsMesoblast Limited hires James M. O'Brien as US-based chief financial officer.Mesoblast Limited, an Australian regenerative medicine company focused on developing innovative cellular medicines to treat inflammatory diseases, has appointed James M. O'Brien as its new US-based chief financial officer.

NewsMesoblast Limited hires Gregory George as Board of Directors.Mesoblast Limited has appointed Dr. Gregory George to its Board.

NewsMesoblast Limited invests into assets: convertible note facility in the amount of $50M.To support the commercial launch of Ryoncil, Mesoblast secured a $50 million convertible note facility with its largest shareholder, available at the company's discretion upon FDA approval.